The National Academies Testimony before Congress

Public Laws Containing Studies for the National Academies

Briefings to Congress

Congressionally Mandated Reports

Policy Statements and Historical Documents

The OCGA staff

THE NATIONAL ACADEMIES
Institute of Medicine
Board on Population Health and Public Health Practice
Committee on Reviewing the HIVNET 012 Perinatal HIV Prevention Study

******

Congressional Briefings
Monday, April 4, 2005
226 Dirksen Senate Office Bldg. -- 3:00 p.m.
and
184 Dirksen Senate Office Bldg. -- 4:30 p.m.

And

Thursday, April 7, 2005
2325 Rayburn House Office Bldg. -- 11:00 a.m.
727 Hart Senate Office Bldg. -- 2:00 p.m.
2125 Rayburn House Office Bldg. -- 3:30 p.m.

on

Review of the HIVNET 012 Perinatal HIV Prevention Study

The HIVNET 012 perinatal HIV prevention trial determined that the drug nevirapine could prevent mother-to-child transmission of HIV. This report, from the Institute of Medicine, reviews the trial's methods and data interpretation, and assesses the validity of its overall findings.

These series of briefings were for members of Congress and congressional staff only. The report was publicly released on April 8, 2005 and can be found, in its entirety, on the Web site of the National Academies Press.